Table of contents
At a glance
What governs IT evidence when manufacturing an ATMP?
Start with the specific ATMP GMP guidelines in EudraLex Part IV and the actual manufacturing process. Other Volume 4 documents apply only where Part IV explicitly references them. For computerised systems, Part IV calls for validation proportionate to the impact on product quality and refers to relevant Annex 11 principles. Link this basis to the required manufacturing and traceability data. A general software release does not demonstrate the chain of identity.
- Use Part IV as the specific basis and ensure references can be clearly traced.
- Link manufacturing records and identity chain across systems in a clear, unambiguous manner.
- Validation scope and failure mitigation are determined based on the actual product effect.
1. Begin with the specific ATMP guideline
EudraLex Part IV contains the GMP guidelines for advanced therapy medicinal products. The version was adopted on 22 November 2017 and was to be implemented by 22 May 2018 at the latest. The current EudraLex index lists it as a specific basis. Its cover sheet expressly delimits that other GMP documents from Volume 4 do not apply automatically, but rather with specific reference.
This is not a general exemption from appropriate quality controls. It requires a precise mapping. Assess the product, development stage, manufacturing steps, and the relevant sections involved. A general Annex 11 list may provide methodological support, but it must not be issued as a complete ATMP evaluation without this requirement chain.
2. Describe the supported manufacturing process
Begin with the technical transitions: incoming raw material, internal labeling, processing, relevant controls, batch evaluation, and product transfer. Assign each step to the corresponding systems or paper-based records that support it. A single platform may perform multiple functions; multiple platforms may collectively form a required record.
For a small team, it is particularly important to clearly identify which data is entered or re-coded at system interfaces. At these points, linkages can be lost, even though each individual data record may appear formally plausible. Describe fields not only in isolation, but also in terms of their meaning: which identifier represents a donation, which material, and which batch? This mapping forms the foundation for subsequent review and verification.
Sources: [1]
3. Link requirements to IT documentation
Our requirement matrix maps selected Part-IV statements to specific validation questions. It is not a complete ATMP-GMP catalog. Its purpose is to align software validation with the required data and decisions, rather than solely verifying the technical installation.
Part IV Section 10.13 refers to proportional validation of computerized systems based on their impact on product quality. Footnote 17 directs to relevant Annex 11 principles. For systems supporting critical processes, provisions for continuity in the event of failure are established. These points must be specifically defined in actual operational use.
| Professional Responsibility | Part IV-Reference | Specific evidential question |
|---|---|---|
| Protect data and ensure availability | §6.13 | Is accuracy, completeness, readability, and appropriate protection ensured? |
| Use valid instruction | §§6.17–6.19 | Is the current instruction available in the correct process and is its modification traceable? |
| Connect the batch history | §§6.26–6.27 and 6.33 | Are relevant steps and separate files clearly assigned? |
| Maintain chain of identity | §§6.35–6.36 | Is bidirectional traceability required? |
| Secure computer systems | §10.13 with footnote 17 | Does the evidence support the intended use and critical fail-safe provisions? |
4. Assess the significance of the linkages
Part IV describes a system enabling bidirectional traceability of cells or tissues contained in the ATMP from donation through manufacturing to the transfer of the finished product to the recipient. The system may be manual or electronic. The required identity verification is therefore not tied to any specific software product.
Traceability includes relevant raw materials and substances that come into contact with cells or tissues within the described scope. Define the required linkages in your manufacturing model. A unique identifier alone is insufficient if it refers to different items in two systems or if an assignment can be altered without a clear and verifiable control mechanism.
Sources: [1]
5. Example: Misassigned Identity Assignment
In the example, a manufacturer processes two separate starting materials designated S-01 and S-02. Starting material S-01 is assigned to manufacturing batch H-01, while starting material S-02 is assigned to manufacturing batch H-02. The following transfer is intended for the designated recipient batches E-01 and E-02, respectively. This simplified chain serves exclusively for intended use verification.
After a data import, two batches remain present. However, the recipient assignments have been swapped. The number of batches matches, but the identity chain does not. Therefore, evaluate both directions using an independently defined reference and assess the system's error response. This case does not establish any actual therapeutic or process architecture.
| Verification | Expected relationship | Controlled error or query | Expected reaction |
|---|---|---|---|
| Forwards S-01 | S-01 → H-01 → E-01 | The import links H-01 to E-02. | Detect deviation; prevent or limit further use according to established procedure |
| S-02 Forward | S-02 → H-02 → E-02 | The import links H-02 to E-01. | Detect swap despite identical dataset size |
| Backward E-01 | E-01 → H-01 → S-01 | Traceback indicates H-02 | Highlight discrepancy to reference |
| Separate finding | The inspection file clearly belongs to H-01. | File name plausible, internal assignment incorrect | Check content linkage, not just file count |
| Closure | Both chains are consistent in both directions. | Correcting the display alone is insufficient | Review affected stored relationships and subsequent expenditures |
Sources: [1]
6. Maintain separate records professionally and logically grouped by function and responsibility
Part IV allows certain batch documentation data to be held in separate files, provided they remain available and are clearly linked to the batch. It does not require copying all the data into one database. Establish how the links and later retrieval will work.
In the example, verify whether a laboratory result can still be correctly attributed after export, renaming, or system change. The required linkage can be supported through controlled identifiers and appropriate context. A simple folder structure without traceable attribution is insufficient. Relevant deviations must remain linked to investigations and corrective actions to ensure the batch history does not consist solely of successful steps.
Sources: [1]
7. Plan for Failure and Changes to the Critical Process
In the event of a system failure, a manual or alternative work procedure may be implemented. Such a procedure must perform the required technical checks under actual operating conditions. A paper form alone does not constitute sufficient evidence of a secure continuation of the identity chain. Verify how data is subsequently reviewed and transferred into the system, and how duplicates or conflicting states are prevented.
Changes to identifiers, interfaces, and instructions may affect the validity of existing records and ongoing manufacturing processes. Assess the impact on current records and ongoing production processes. Appropriate third-party documentation may contribute; Part IV explicitly addresses the evaluation of adequate coverage and, if necessary, additional on-site verification during supplier qualification.
Sources: [1]
8. Checklist for the IT Requirement Card
The closure should demonstrate which specific ATMP activity is supported by which specific evidence. A general document titled "GMP-compliant" is less helpful than a clear linkage between responsibility, data transfer, and inspection results. Also identify the remaining questions and their significance for the intended use.
Our checklist focuses on manufacturing and identity data. Additional ATMP requirements, such as specific biological risks or product release criteria, must be addressed separately in the relevant procedure. They are supported by an appropriate IT audit, but are not replaced by it.
- Part IV – Scope and relevant specific references defined.
- Manufacturing steps, systems and data ownership are documented.
- Identifications with their technical significance are clearly assigned.
- Traceability in both directions including transitions verified.
- Separate files and relevant deviations are linked to the batch.
- Critical failure mitigation and subsequent data transfer considered.
- Evidence, open questions, and permissible use traceable and justified.
Project experience and collaboration
Preserve the chain of identity across systems
With your ATMP process owners, we trace the relationships between starting material, manufacturing, testing and administration. An identity passed between systems must remain traceable through a correction or system change. An existing unique identifier may provide a sound basis. Manually transcribed or subsequently merged links need their own controls. We also identify records requiring long-term retention and how their context will be retrieved. The evidence follows your actual ATMP process.
Frequently asked questions about IT evidence and identity data in ATMP manufacturing
Does Annex 11 remain unchanged in its general applicability to every ATMP system?
Part IV is the specific basis for ATMP; other volume 4 documents only apply if explicitly referred to. For computer systems, No. 10.13 above footnote 17 refers to the principles of Annex 11. Validation must be designed in accordance with the effect on product quality; the entire Annex 11 application must not be derived solely from the product name.
Is Part IV an exception to computerized system validation?
No. Section 10.13 refers to a validation whose scope is aligned with its impact on product quality. For critical processes, continuity during system failure must also be considered. The specific basis requires appropriate safeguards, not automatic release.
Sources: [1]
Must the identity chain be maintained electronically?
Part IV describes a manual or electronic traceability system. Crucially, the required linkage must be reliably established. The selection of the medium does not substitute for verification of accuracy, completeness, availability, and unambiguous assignment.
Sources: [1]
What does bidirectional traceability mean?
The required chain must be traceable from donation through manufacturing and product transfer to the recipient, and in reverse direction as well. The information and transfers required for this traceability depend on the specific product and manufacturing process. A forward-only list does not automatically address reverse tracing requirements.
Sources: [1]
Why does the number of batches in the example of this article not suffice?
Two existing batches may still be linked to incorrect recipients. Quantity integrity and identity integrity represent distinct assertions. The as-builts therefore verify the specific relationships and their traceability against an independently defined reference.
Sources: [1]
Can laboratory and manufacturing data be stored in separate systems?
Yes. Separate storage is possible. Part IV requires separately maintained batch data to remain available and clearly linked to the corresponding batch. Verify that link across exports and systems.
Sources: [1]
Does every Advanced Therapy Medicinal Product (ATMP) manufacturer require the same test package?
No. The product, development stage, manufacturing process, and system functionality influence the required safeguards. The specific guideline includes differentiated requirements. A general test list may provide orientation but does not replace the evaluation of the specific usage scenario.
Sources: [1]
Can a paper-based process mitigate an IT outage?
It may constitute part of an appropriate alternative if it genuinely supports the critical process. Verify identity controls, required information, and subsequent data transfer. The availability of a form alone does not establish effective continuity.
Sources: [1]
Does the supplier provide qualified qualification documentation?
Part IV describes the evaluation of whether provided documentation is sufficient or whether additional inspections are required. The key factor is its coverage of the intended manufacturing process and actual usage. An unverified full acceptance or blanket rejection would be undifferentiated and inappropriate.
Sources: [1]
How long must ATMP batch and traceability data be retained?
Part IV distinguishes different record types. Section 6.37 sets a minimum of 30 years after product expiry for the traceability data it specifies, subject to a longer period in the marketing authorisation. For batch documentation, section 6.32 gives the later of one year after batch expiry and at least five years after QP certification. For investigational medicinal products, the minimum is five years from completion or formal discontinuation of the last clinical trial to use the batch. Plan to retain the links and readability when systems change.
Sources: [1]
Sources and review date
Source date: 7 October 2026. Regulatory requirements, guidelines, and industry practices must be categorized separately. Tables, figures, and case examples are to be considered standalone reference materials; they do not constitute completed product testing.
- European Commission: GMP specific to Advanced Therapy Medicinal ProductsEudraLex Volume 4 Part IV, 22 November 2017, applicable by 22 May 2018. Sections 6.13, 6.17–6.19, 6.26–6.27, 6.33, 6.35–6.36, 10.13 with footnote 17, and 10.26. We also reviewed section 6.32 on batch documentation and section 6.37 on the specified traceability data on 18 October 2026.
- European Commission: EudraLex Volume 4Status as of 07.10.2026; Human medicinal products and veterinary law separated.
- EU GMP Annex 11 – Computerised SystemsRevision January 2011; listed in the human medicinal product section. Principle, §§1–17.
Sources checked: .
Jointly develop the specific evidence process
We support your team in linking the ATMP-specific foundation with manufacturing data, identity transfers, and the required IT evidence.
- Computer system validation →
Bring your GxP systems into validated operation, from laboratory software, MES and eQMS to ERP. We define the scope, plan risk-based tests using GAMP 5 and hand the evidence to QA for release.

